Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Intervalo de año de publicación
1.
Nanotechnology ; 25(20): 205301, 2014 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-24784353

RESUMEN

We fabricate site-controlled, ordered arrays of embedded Ga nanoparticles on Si, using a combination of substrate patterning and molecular-beam epitaxial growth. The fabrication process consists of two steps. Ga droplets are initially nucleated in an ordered array of inverted pyramidal pits, and then partially crystallized by exposure to an As flux, which promotes the formation of a GaAs shell that seals the Ga nanoparticle within two semiconductor layers. The nanoparticle formation process has been investigated through a combination of extensive chemical and structural characterization and theoretical kinetic Monte Carlo simulations.

2.
Nanoscale Res Lett ; 5(12): 1905-7, 2010 Aug 31.
Artículo en Inglés | MEDLINE | ID: mdl-21170400

RESUMEN

We propose a self-assembling procedure for the fabrication of GaAs islands by Droplet Epitaxy on silicon substrate. Controlling substrate temperature and amount of supplied gallium is possible to tune the base size of the islands from 70 up to 250 nm and the density from 10(7) to 10(9) cm(-2). The islands show a standard deviation of base size distribution below 10% and their shape evolves changing the aspect ratio from 0.3 to 0.5 as size increases. Due to their characteristics, these islands are suitable to be used as local artificial substrates for the integration of III-V quantum nanostructures directly on silicon substrate.

3.
Pharmacol Res ; 43(4): 341-7, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11352539

RESUMEN

The developmental and behavioral outcomes of uninterrupted exposure to vanadium was studied in the rat. Starting 3 days before birth and up to the 100th day of extrauterine life, rats received as drink either a water solution of vanadyl sulphate (300 mg l(-1)containing 70 mg l(-1)of vanadium element, which is equal to an ingested dose of about 10 mg kg(-1)per day of vanadium element) plus NaCl 5 g l(-1), or a water solution of NaCl 5 g l(-1), or plain water [up to weaning (25th day of extrauterine life) treatment was given to dams and offspring]. At weaning, survivors were fewer and body weight was found to be significantly lower in the offspring of vanadium plus NaCl-treated dams than in the offspring of the other two groups. After weaning, growth retardation continued to be significant in both vanadium plus NaCl- and NaCl-treated rats. Such an effect was more pronounced in males than in females. Locomotor activity--evaluated at 1 month of age--was not significantly different in the three groups of rats. In the open-field, male (but not female) vanadium plus NaCl-treated rats had a reduced outer ambulation, rearing posture and grooming activity, and an increased defecation, in comparison with the males of the NaCl group, and reduced rearing in comparison with control males. As concerns ingestive behaviors, the only significant datum was an increased water intake in NaCl-treated males. Finally, at the 100th day of life, working memory was significantly impaired in both vanadium plus NaCl- and NaCl-treated rats.


Asunto(s)
Conducta Animal/efectos de los fármacos , Crecimiento/efectos de los fármacos , Efectos Tardíos de la Exposición Prenatal , Vanadio/toxicidad , Animales , Animales Recién Nacidos , Peso Corporal/efectos de los fármacos , Ingestión de Líquidos/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Femenino , Masculino , Memoria/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Embarazo , Ratas , Ratas Wistar , Cloruro de Sodio/administración & dosificación , Cloruro de Sodio/farmacología , Tasa de Supervivencia , Vanadio/administración & dosificación , Destete
4.
J Biol Chem ; 276(27): 25197-207, 2001 Jul 06.
Artículo en Inglés | MEDLINE | ID: mdl-11297555

RESUMEN

Islet-specific glucose-6-phosphatase (G6Pase) catalytic subunit-related protein (IGRP) is a homolog of the catalytic subunit of G6Pase, the enzyme that catalyzes the terminal step of the gluconeogenic pathway. Its catalytic activity, however, has not been defined. Since IGRP gene expression is restricted to islets, this suggests a possible role in the regulation of islet metabolism and, hence, insulin secretion induced by metabolites. We report here a comparative analysis of the human, mouse, and rat IGRP genes. These studies aimed to identify conserved sequences that may be critical for IGRP function and that specify its restricted tissue distribution. The single copy human IGRP gene has five exons of similar length and coding sequence to the mouse IGRP gene and is located on human chromosome 2q28-32 adjacent to the myosin heavy chain 1B gene. In contrast, the rat IGRP gene does not appear to encode a protein as a result of a series of deletions and insertions in the coding sequence. Moreover, rat IGRP mRNA, unlike mouse and human IGRP mRNA, is not expressed in islets or islet-derived cell lines, an observation that was traced by fusion gene analysis to a mutation of the TATA box motif in the mouse/human IGRP promoters to TGTA in the rat sequence. The results provide a framework for the further analysis of the molecular basis for the tissue-restricted expression of the IGRP gene and the identification of key amino acid sequences that determine its biological activity.


Asunto(s)
Glucosa-6-Fosfatasa/genética , Proteínas/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Dominio Catalítico , Clonación Molecular , Secuencia Conservada , Glucosa-6-Fosfatasa/química , Humanos , Técnicas para Inmunoenzimas , Ratones , Datos de Secuencia Molecular , Regiones Promotoras Genéticas , Proteínas/química , ARN Mensajero/análisis , Ratas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Alineación de Secuencia
5.
Mol Endocrinol ; 14(4): 535-44, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10770490

RESUMEN

Mutants isolated from the Y1 mouse adrenocortical tumor cell line (clones 10r-9 and 10r-6) are resistant to ACTH because they fail to express the melanocortin-2 receptor (MC2R). In this study, we show that a luciferase reporter plasmid driven by 1,800 bp of the proximal promoter region of the MC2R was expressed poorly in the mutant cells compared with parent Y1 cells. The differential expression of the MC2R in parent and mutant cells resulted from impaired activity of the orphan nuclear receptor NR5A1 (SF1) on the promoter as determined by 5'-deletion analysis. Furthermore, the activity of an SF1 expression plasmid on an SF1-dependent reporter plasmid was compromised in mutant clones. The site-specific DNA binding properties of SF1 from parent and mutant cells did not differ as determined in electrophoretic mobility shift assays, and the addition of the activation domain of VP16 to the amino terminus of SF1 restored the transcriptional activity of the protein. In addition, the levels of SF1 and other cofactors including WT1, CBP/p300, and steroid receptor coactivator 1 did not differ appreciably between parent and mutant cells. Taken together, these results suggest that ACTH resistance in the mutant clones resulted from a defect that affected the activation properties of SF1 rather than its DNA binding activity. Consistent with the observed impairment in SF1 function, other SF1-dependent genes, including Cyp11b1 and steroidogenic acute regulatory protein (StAR), were poorly expressed and global steroidogenesis, as evidenced by the metabolism of 22(R)-hydroxycholesterol to steroid products, was impaired. Interestingly, MC2R, Cyp11a, Cyp11b1, and StAR transcripts were not affected to the same degree, suggesting that each of these genes may have a different absolute requirement for SF1. These mutants thus provide an experimental paradigm to identify factors that influence SF1 function and to evaluate the relative importance of SF1 in the expression of genes essential for adrenal steroidogenesis.


Asunto(s)
Neoplasias de la Corteza Suprarrenal/genética , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Mutación , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Corticoesteroides/biosíntesis , Corticoesteroides/genética , Neoplasias de la Corteza Suprarrenal/metabolismo , Hormona Adrenocorticotrópica/farmacología , Animales , ADN/metabolismo , Resistencia a Medicamentos , Factores de Transcripción Fushi Tarazu , Expresión Génica , Proteínas de Homeodominio , Luciferasas/genética , Ratones , Fosfoproteínas/genética , Regiones Promotoras Genéticas , Receptores de Corticotropina/genética , Receptores Citoplasmáticos y Nucleares , Receptores de Melanocortina , Proteínas Recombinantes de Fusión , Esteroide 11-beta-Hidroxilasa/genética , Factor Esteroidogénico 1 , Transcripción Genética , Células Tumorales Cultivadas
6.
Endocr Res ; 26(4): 1005-9, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11196409

RESUMEN

This study explores the basis for the altered function of steroidogenic factor-1 (SF1) in a family of ACTH-resistant Y1 adrenal cell mutants. As determined in electrophoretic mobility shift assays, the DNA binding activity of SF1 was not impaired in the mutant clones. Instead, the ability of SF1 to interact with the coactivator, GRIP1 was affected as determined in a modified mammalian 2-hybrid assay. These findings indicate that the mutants harbor a defect affecting the activation function of SF1.


Asunto(s)
Neoplasias de la Corteza Suprarrenal/genética , Hormona Adrenocorticotrópica/farmacología , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/fisiología , Mutación/fisiología , Factores de Transcripción/genética , Factores de Transcripción/fisiología , Neoplasias de la Corteza Suprarrenal/patología , Animales , Resistencia a Medicamentos , Sinergismo Farmacológico , Factores de Transcripción Fushi Tarazu , Proteínas de Homeodominio , Ratones , Coactivador 2 del Receptor Nuclear , Receptores Citoplasmáticos y Nucleares , Factor Esteroidogénico 1 , Células Tumorales Cultivadas
7.
Mol Endocrinol ; 12(12): 1879-87, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9849962

RESUMEN

Mutant Y1 mouse adrenocortical tumor cells, isolated on the basis of their resistance to the growth-inhibitory effects of forskolin, arise from single mutational events. These mutants present complex phenotypes in which the activity of Gbeta/gamma is impaired, ACTH receptor gene expression is markedly diminished, and ACTH-responsive adenylyl cyclase activity is lost. In this study, we have tested the hypothesis that the impairment in Gbeta/gamma activity is responsible for the loss of ACTH receptor gene expression and ACTH-responsive adenylyl cyclase activity. Transfection of one of the mutant clones with expression vectors encoding either Gbeta1 or Gbeta2 together with Ggamma2 increased ACTH receptor expression and restored ACTH-responsive adenylyl cyclase activity. Interestingly, either Gbeta2 or Ggamma2 alone was effective. These results thus support the hypothesis that the impairment in Gbeta/gamma activity is responsible for the loss of ACTH receptor expression. A luciferase reporter plasmid driven by the proximal promoter region of the mouse ACTH receptor gene was expressed poorly in the mutants compared with parental Y1 cells, suggesting that the Gbeta/gamma defect compromised transcriptional activity at the proximal promoter region of the ACTH receptor gene.


Asunto(s)
Proteínas de Unión al GTP/fisiología , Expresión Génica , Receptores de Corticotropina/genética , Adenilil Ciclasas/metabolismo , Hormona Adrenocorticotrópica/farmacología , Animales , Bovinos , AMP Cíclico/metabolismo , Proteínas de Unión al GTP/química , Proteínas de Unión al GTP/genética , Vectores Genéticos , Humanos , Luciferasas/genética , Ratones , Datos de Secuencia Molecular , Mutación , Regiones Promotoras Genéticas , ARN Mensajero/análisis , Receptores de Corticotropina/fisiología , Transfección
8.
Braz J Med Biol Res ; 29(3): 343-5, 1996 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8736127

RESUMEN

Adrenocorticotropic hormone (ACTH) triggers well-defined responses in Y-1 cells. Among them is steroidogenesis stimulation. We have previously shown that phorbol 12-myristate 13-acetate (PMA), an activator of the calcium- and phospholipid-dependent protein kinase (PKC) is able to mimic all the responses triggered by ACTH in these cells, including steroidogenesis stimulation. Short (2 h) treatment with PMA leads to only 20-30% of the maximal steroidogenesis stimulation obtained with ACTH. However, the steroid secretion in the 2 h that follows the short-term (2 h) PMA treatment reaches the same levels as observed with ACTH, i.e., a 12- to 15-fold increase. We also show that this effect is restricted to cells treated with PMA for up to 4 h, while treatment for longer periods of time causes a reduction of the steroid biosynthesis rate, an effect that is not observed in cells treated with ACTH or N6,2'-0-dibutyryladenosine 3',5'-cyclic monophosphate (dcAMP). These results suggest that activation of PKC can elicit the first phase of ACTH steroidogenesis stimulation, but not the second one, which strictly depends on activation of cAMP-dependent protein kinase.


Asunto(s)
Hormona Adrenocorticotrópica/metabolismo , AMP Cíclico/metabolismo , Ésteres del Forbol/metabolismo , Esteroides/biosíntesis , Hormona Adrenocorticotrópica/fisiología
9.
Braz. j. med. biol. res ; 29(3): 343-5, Mar. 1996. tab, graf
Artículo en Inglés | LILACS | ID: lil-163841

RESUMEN

Adrenocorticotropic hormone (ACTH) triggers well-defined responses in Y-1 cells. Among them is steroidogenesis stimulation. We have previously shown that phorbol 12-myristate 13-acetate (PMA), an activator of the calcium- and phospholipid-dependent protein kinase (PKC) is able to mimic all the responses triggered by ACTH in these cells, including steroidogenesis stimulation. Short (2 h) treatment with PMA leads to only 20-30 per cent of the maximal steroidogenesis stimulation obtained with ACTH. However, the steroid secretion in the 2 h that follows the short-term (2 h) PMA treatment reaches the same levels as observed with ACTH, i.e., a 12- to 15-fold increase. We also show that this effect is restricted to cells treated with PMA for up to 4 h, while treatment for longer periods of time causes a reduction of the steroid biosynthesis rate, an effect that is not observed in cells treated with ACTH or N6,2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dcAMP). These results suggest that activation of PKC can elicit the first phase of ACTH steroidogenesis stimulation, but not the second one, which strictly depends on activation of cAMP-dependent protein kinase.


Asunto(s)
Hormona Adrenocorticotrópica/metabolismo , AMP Cíclico/metabolismo , Ésteres del Forbol/metabolismo , Esteroides/biosíntesis , Hormona Adrenocorticotrópica/fisiología
10.
Mol Cell Biochem ; 124(1): 23-32, 1993 Jul 07.
Artículo en Inglés | MEDLINE | ID: mdl-7694073

RESUMEN

We previously reported that ACTH, but not dibutyryl cAMP, rapidly induces the c-fos proto-oncogene in Y-1 adrenocortical cells. Here we show that PMA induces c-fos with similar kinetics when compared with ACTH (0.5-1 h peak) but reaches only 60% of the maximal ACTH induction and dcAMP is a weak c-fos inducer (15% of ACTH). However, combination of PMA and dcAMP has a synergistic effect leading to maximal c-fos induction. c-fos expression may play a role in the RNA synthesis-dependent corticosteroidogenesis response and/or growth regulation by ACTH. We also show that, in contrast to dcAMP, PMA is a poor steroidogenesis stimulator (15 to 17% of maximum ACTH-stimulated level), its activity being completely dependent on RNA synthesis. Combination of dcAMP and PMA yields an additive steroidogenesis stimulation, an effect that is also dependent on RNA synthesis. Although no strict correlation was found between c-fos induction and early steroidogenesis stimulation, particularly with respect to cAMP derivatives, the results suggest that a PKC pathway is likely to cooperate with the classical cAMP-PKA pathway in adrenal cells' RNA-dependent steroidogenesis.


Asunto(s)
Corteza Suprarrenal/metabolismo , Hormona Adrenocorticotrópica/farmacología , Bucladesina/farmacología , Proteínas Proto-Oncogénicas c-fos/genética , Esteroides/biosíntesis , Acetato de Tetradecanoilforbol/farmacología , Corteza Suprarrenal/citología , Corteza Suprarrenal/efectos de los fármacos , Animales , Células Cultivadas , Sinergismo Farmacológico , Expresión Génica/efectos de los fármacos , Ratones , Proteína Quinasa C/metabolismo , Proto-Oncogenes , ARN/metabolismo , Porcinos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...